Edison Investment Research - Amoeba SA (AMEBA) Amoeba - Biocontrol plant paves path to commercialisation

Report

Edison Investment Research

Toby Thorrington

Amoeba - Biocontrol plant paves path to commercialisation

Thus far, FY23 has marked a year of successful advancement for Amoéba: (1) the development of its biocontrol plant is ongoing, poised to achieve production of 40 tonnes per annum of W. magna lysate; (2) a third scientific article has been published, which highlights the efficacy of its biocontrol product; and (3) the company has announced a potential further application for W. magna lysate in cosmetic skincare. The new application will not hinder advancement of the biological fungicide product. H123 saw the widening of EBIT losses by €1.0m y-o-y to €3.9m, primarily attributable to increased industrial deployment costs and financing fees; Amoéba plans to seek €45m financing to support its expansion and operations.

16/11/2023 1 EN

Underlying

Amoeba SA

Amoeba SA. Amoeba SA is a France-based company that develops, manufactures and markets biological products. The Company specializes in disruptive biological solutions for the treatment of Legionella, amoeba and biofilm in water. The Company's offering includes products and services, such as: Cleantech biological solution, a patented technological disruptive product with no impact on the environment; amoebic analyses of waters of wet cooling towers (TAR), hot sanitary waters, industrial waters and waters of swimming pools; as well as Legionella tests of industrial waste water, among others. The Company is engaged in various technical, commercial, industrial and investment partnerships.

See profile

FR0011051598 Euronext Paris France

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Toby Thorrington

Other Reports on these Companies

Portzamparc Sponsored

La Matinale - 22-06-2023

LA VALEUR DU JOUR : ACTIA GROUP : Feedback Conférence Portzamparc – Conserver (3), obj. 4.70€ Cours: 4.67€ au 21/06/23 AFYREN : Feedback Conférence Portzamparc – Acheter (1), obj. 9.40€ Cours: 5.70€ au 21/06/23 AMOEBA : Feedback Conférence Portzamparc – Acheter (1), obj. 0.72€ Cours: 0.58€ au 21/06/23 BENETEAU : Feedback Conférence Portzamparc – Acheter (1), obj. 23.0€ Cours: 15.3€ au 21/06/23 EXAIL TECHNOLOGIES : Feedback Conférence Portzamparc – Acheter (1), obj. 26.5€ Cours: 20.2€ au 21/06/23 EXEL INDUSTRIES : Feedback Conférence Portzamparc – Conserver (3), obj. 56.0€ Cours: 50.2€ au...

June 22, 2023 June 22, 2023 1 FR

Edison Investment Research

Amoeba - Scaling up for commercialisation

Following on from the press release in March that provided preliminary data on the FY22 results, Amoéba has published its FY22 universal registration document, which contains detailed financial information for the year. We leave our FY23 estimates unchanged.

May 22, 2023 May 22, 2023 1 EN

Picton Property Income - Unlocking value to drive DPS growth

Ahead of FY24 results to be published on 23 May, Picton Property Income has declared a Q424 DPS of 0.925p, a 5.7% increase on the previous quarter. The company intends to maintain fully covered dividends at the new level, an annualised run rate of 3.7p, well above the pre-pandemic DPS and the 3.5p paid in respect of FY24. The uplift reflects a continuing robust occupier market, supporting rental growth, as well as asset management activity, most notably the recent sale of Angel Gate. The sale was part of Picton’s strategy to accelerate the unlocking of value in its portfolio through the select...

1h / 30m 1h / 30m 1 EN

Sean Conroy

Sean Conroy

AFT Pharmaceuticals - Maxigesic IV’s Brazil entry, a foray into LATAM

AFT continues to expand its Maxigesic IV footprint with the announcement of a licensing agreement in Brazil, the largest pharma market in South America and tenth largest market globally. The deal signed with Halex Istar, a leading manufacturer of injectables in the country, provides a strong foundation for further extension into the Latin American and global markets, an overarching long-term goal for AFT. Maxigesic IV is a higher-strength version of AFT’s proprietary paracetamol plus ibuprofen formulation targeting post-surgical pain relief in the hospital setting. It is currently available in...

1h / 46m 1h / 46m 1 EN

Fiona Orford-Williams

Fiona Orford-Williams

The Pebble Group - Two distinct businesses in one

The Pebble Group’s AGM update confirms that trading is in line with FY24 expectations, with attractive opportunities for its two distinct businesses in the large, fragmented promotional products sector. Facilisgroup is a SaaS business, helping North American distributors to optimise their operations, with access to an approved supplier roster. Brand Addition services global brands’ needs for branded product for in-house and external programmes. The well-publicised dip in tech sector marketing spend was a key factor in Pebble’s Q423 outlook revision. Both segments are now well placed to benefit...

20h / 31m 20h / 31m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Amoeba - Biocontrol plant paves path to commercialisation

La Matinale - 22-06-2023

Amoeba - Scaling up for commercialisation

Picton Property Income - Unlocking value to drive DPS growth

AFT Pharmaceuticals - Maxigesic IV’s Brazil entry, a foray into LATAM

The Pebble Group - Two distinct businesses in one

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe